Quantcast
The MFWire
Manage Email Alerts | Sponsorships | About MFWire | Who We Are

Subscribe to MFWire.com's News Alerts [click]

Rating:Monument Erects Sector Fund Not Rated 3.0 Email Routing List Email & Route  Print Print
Tuesday, May 25, 1999

Monument Erects Sector Fund

Reported by Jason Shank

Monument Funds Group, best known for its hot sector fund, the Monument Internet Fund, is expanding its fund family with the launch of the Monument Medical Sciences Fund (CUSIP # 614907103).

"The launch of the Monument Medical Sciences Fund is a logical extension of our expertise in sector/specialty funds and an important component in rounding out our fund family," explains Monument Funds Group president David A. Kugler. "As Baby Boomers close in on their retirement years, we are facing the prospect of a U.S. population that will soon have its highest concentration in the over-65 demographic. To serve this population, innovative solutions in disease management and effective healthcare will be increasingly important. Launching this fund -- with this focus at this particular point in time -- positions Monument shareholders to take advantage of what is likely be a long period of sustained growth in the medical sciences sector."

The Monument Medical Sciences Fund is a long-term capital appreciation equity fund, which invests only in companies involved in research development, production and distribution of medical products and services. This includes pharmaceutical firms, medical supply design, manufacturing and sales companies, equipment and support services, and companies engaged in medical, diagnostic, biochemical and biotechnological R&D.

"There was a time when biotech was the subject of considerable hype that it just wasn't able to live up to," said Monument Advisors senior vice president and portfolio manager Alexander C. Cheung, who also manages the Monument Internet fund. "Now, the medical sciences consumer market and its products are finally poised to come together in a very powerful way. For example, the combination of the aging population and the fact that more than 200 drugs are now in the final stages of their 12-year testing process means the time is ripe for investment in these companies." 

Stay ahead of the news ... Sign up for our email alerts now
CLICK HERE

3.0
 Do You Recommend This Story?



GO TO: MFWire
Return to Top
 News Archives
2024: Q2Q1
2023: Q4Q3Q2Q1
2022: Q4Q3Q2Q1
2021: Q4Q3Q2Q1
2020: Q4Q3Q2Q1
2019: Q4Q3Q2Q1
2018: Q4Q3Q2Q1
2017: Q4Q3Q2Q1
2016: Q4Q3Q2Q1
2015: Q4Q3Q2Q1
2014: Q4Q3Q2Q1
2013: Q4Q3Q2Q1
2012: Q4Q3Q2Q1
2011: Q4Q3Q2Q1
2010: Q4Q3Q2Q1
2009: Q4Q3Q2Q1
2008: Q4Q3Q2Q1
2007: Q4Q3Q2Q1
2006: Q4Q3Q2Q1
2005: Q4Q3Q2Q1
2004: Q4Q3Q2Q1
2003: Q4Q3Q2Q1
2002: Q4Q3Q2Q1
 Subscribe via RSS:
Raw XML
Add to My Yahoo!
follow us in feedly




©All rights reserved to InvestmentWires, Inc. 1997-2024
14 Wall Street | 20th Floor | New York, NY 10005 | P: 212-331-8968 | F: 212-331-8998
Privacy Policy :: Terms of Use